The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1529
ISSUE1529
September 11, 2017
Safinamide (Xadago) for Parkinson's Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Safinamide (Xadago) for Parkinson's Disease
September 11, 2017 (Issue: 1529)
The FDA has approved the monoamine oxidase
type B (MAO-B) inhibitor safinamide (Xadago – US
Worldmeds) as an adjunct to levodopa/carbidopa
for management of "off" episodes in patients with
Parkinson’s disease (PD). It is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.